Financial Performance - Net profit attributable to shareholders decreased by 50.09% to CNY 33,329,362.29 for the first nine months of 2024, down from CNY 66,783,324.30 in the same period of 2023[4] - Operating revenue for the first nine months of 2024 was CNY 116,290,891.37, a decline of 29.94% compared to CNY 165,979,586.54 in the previous year[4] - Operating profit for the first nine months of 2024 was ¥38,287,916.96, down from ¥77,645,770.59 in 2023, indicating a decrease of about 51%[18] - Total revenue for the first nine months of 2024 reached ¥116,290,891.37, a decrease from ¥165,979,586.54 in the same period of 2023, representing a decline of approximately 30%[16] - The total comprehensive income attributable to the parent company was 33,329,362.29 CNY, a decrease from 66,783,324.30 CNY in the previous period[19] Cash Flow - Cash flow from operating activities decreased by 65.12% to CNY 19,884,202.52, down from CNY 57,012,225.72 in the same period last year[4] - Cash inflow from operating activities totaled 98,018,579.47 CNY, compared to 136,450,839.80 CNY in the same period last year, representing a decline of approximately 28.1%[20] - Net cash flow from operating activities was 19,884,202.52 CNY, significantly lower than 57,012,225.72 CNY in the previous year[20] - Cash inflow from investment activities was 845,250,000.00 CNY, with cash outflow totaling 1,118,339,644.78 CNY, resulting in a net cash flow from investment activities of -273,089,644.78 CNY[21] - Cash inflow from financing activities was 386,848,100.00 CNY, while cash outflow was 48,175,600.00 CNY, leading to a net cash flow from financing activities of 338,672,500.00 CNY[21] - The net increase in cash and cash equivalents was 86,094,945.26 CNY, contrasting with a decrease of 37,595,731.78 CNY in the previous period[21] - The ending balance of cash and cash equivalents was 185,185,244.67 CNY, up from 102,149,501.75 CNY in the previous year[21] Assets and Liabilities - Total assets increased by 119.25% to CNY 673,930,475.67 as of September 30, 2024, compared to CNY 307,375,267.23 at the end of 2023[4] - Total current assets increased to ¥508,255,966.03 as of September 30, 2024, compared to ¥178,234,543.26 at the end of 2023, representing a growth of approximately 185.5%[12] - Total liabilities amounted to ¥38,787,585.70, while total equity reached ¥635,142,889.97, indicating a strong equity position[14] - The company’s total liabilities to assets ratio remained low at 5.76% as of September 30, 2024, unchanged from the previous year[4] - The total non-current assets rose to ¥165,674,509.64 in 2024 from ¥129,140,723.97 in 2023, an increase of approximately 28%[14] Shareholder Information - The total number of shareholders holding more than 5% of shares is 10, with a combined holding of 63,065,900 shares, representing 78.83% of total shares[9] - The company completed a public offering, resulting in a 33.33% increase in share capital to CNY 80,000,000.00[5] Research and Development - Research and development expenses for the first nine months of 2024 were ¥6,151,349.94, slightly lower than ¥7,082,359.06 in 2023, showing a decrease of about 13%[16] Other Information - No significant legal disputes or external guarantees were reported during the reporting period[11] - The company has not engaged in any major asset acquisitions or disposals during the quarter[11] - Non-recurring gains and losses amounted to CNY 476,938.81, with a net amount of CNY 405,397.99 after tax effects[7] - The company reported a decrease in operating costs to ¥79,543,652.56 in 2024 from ¥89,073,883.49 in 2023, a reduction of approximately 11%[16] - Deferred income decreased to ¥429,121.48 in 2024 from ¥661,692.40 in 2023, indicating a decline of about 35%[14] - The company’s capital reserve increased significantly to ¥344,418,713.16 in 2024 from ¥6,998,030.11 in 2023, reflecting a growth of over 4,800%[14] - Cash and cash equivalents rose to ¥186,341,856.34 from ¥101,382,799.16, marking an increase of about 83.9%[12] - Trading financial assets amounted to ¥256,000,000.00, with no previous balance reported[12] - Accounts receivable decreased to ¥20,631,299.26 from ¥31,942,433.20, a decline of approximately 35.2%[12] - Inventory stood at ¥27,051,865.27, slightly down from ¥28,592,659.82, a decrease of about 5.4%[12] - Fixed assets increased to ¥70,900,342.13 from ¥56,304,746.58, reflecting a growth of approximately 25.9%[12] - Construction in progress rose to ¥56,713,845.91 from ¥37,472,611.67, an increase of about 51.3%[12] - The company’s basic earnings per share dropped by 61.26% to CNY 0.43 from CNY 1.11 year-on-year[4] - Basic and diluted earnings per share were both 0.43 CNY, down from 1.11 CNY[19]
海昇药业(870656) - 2024 Q3 - 季度财报